Lilly's New Drug Retatrutide Outperforms Ozempic in Trial

• Eli Lilly's new drug, retatrutide, outperformed Ozempic in a head-to-head clinical trial.
• Participants taking retatrutide lost approximately twice as much weight as those on Ozempic.
• Retatrutide achieved a 2.2 percentage-point reduction in blood sugar levels, measured by A1c, surpassing Ozempic.
• Retatrutide is still in clinical development and has not yet been approved by the FDA.
• The trial results have been reported by multiple reputable sources including Reuters, Business Insider, and STAT.